GLAXOSMITHKLINE PLC Form 6-K July 28, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 28 July 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

CEO b) Position/status

c) Initial notification/

Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Sale of Ordinary Shares on

b) Nature of the transaction 27 July 2016 at a price of

£16.9350.

c) Price(s) and volume(s) Price(s) Volume(s) £16.9350 10,000

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2016-07-27

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr D S Redfern a) Name b)Position/status Chief Strategy Officer

c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b)LEI

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

The exercise of options over

26,800 Ordinary Shares,

granted on 20 February 2007 under the GlaxoSmithKline

Share Option Plan.

Price(s)

2016-07-27

Price(s) and

Volume(s)

volume(s) £14.88

26,800 n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

Initial notification/

Initial notification amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

b) Nature of the transaction

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

The sale of 26,800 Ordinary

Shares following the

exercise of options granted on 20 February 2007 under

the GlaxoSmithKline Share

Option Plan.

Price(s) c) Price(s) and Volume(s) volume(s) £16.942 26,800 n/a (single transaction) Aggregated information d) Aggregated volume Price e) Date of the transaction 2016-07-27 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D S Redfern b)Position/status Chief Strategy Officer c) Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b)LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 The exercise of options over 24,186 Ordinary Shares, granted on 19 February 2008 b) Nature of the transaction under the GlaxoSmithKline Share Option Plan. c) Price(s) and volume(s) Price(s) Volume(s) £11.47 24,186 n/a (single transaction) Aggregated information d) Aggregated volume Price e) Date of the transaction 2016-07-27 Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern b) Position/status Chief Strategy Officer

Initial notification/

amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

The sale of 24,186 Ordinary

Shares following the

exercise of options granted on granted on 19 February

b) Nature of the transaction 2008 under the

GlaxoSmithKline Share

Option Plan.

 $\begin{array}{ccc} \text{Price(s) and} & \text{Price(s)} & \text{Volume(s)} \\ \text{volume(s)} & \text{£16.938} & \text{24,186} \end{array}$ 

Aggregated information n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction 2016-07-27

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern b) Position/status Chief Strategy Officer

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

The exercise of options over 2,614 Ordinary Shares, granted on 19 February 2008

under the GlaxoSmithKline

Share Option Plan.

Price(s) and Price(s) Volume(s)
volume(s) £11.47 2,614
n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-07-28

Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern b) Position/status Chief Strategy Officer

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February

b) Nature of the transaction 2008 under the

GlaxoSmithKline Share

Option Plan.

Price(s) and Price(s) Volume(s)  $$\mathfrak{t}17.035$$  Volume(s)

n/a (single transaction)

d)

Aggregated volume Price

Aggregated information

e) Date of the transaction 2016-07-28

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status

Senior Vice President,
Human Resources

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market participant, auction

"platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Sale of Ordinary Shares on

28 July 2016 at a price of

b) Nature of the transaction £16.9757.

Price(s) and Price(s) Volume(s) \$\frac{\pmathbf{t}16.9757}{\pmathbf{t}}\$ 43,000

n/a (single transaction)

Aggregated information

Aggregated volume Price

d)

e) Date of the transaction 2016-07-28

Place of the transaction London Stock Exchange

(XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: July 28, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc